Finance

Lists
SNW:ETR
Sanofi SA
€84,86
+1,30%
(+1,09) 1D
20 Nov., 17:35:55 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for SNW...
Open
€84,20
High
€85,50
Low
€84,20
Mkt. cap
102,57 mjd.
Avg. vol.
15,14 k
Volume
10,50 k
P/E ratio
24,40
52-wk high
€88,99
52-wk low
€69,77
EPS
€3,48
Shares outstanding
1,25 mjd.
No. of employees
75 k
Open
€84,20
High
€85,50
Low
€84,20
Mkt. cap
102,57 mjd.
Avg. vol.
15,14 k
Volume
10,50 k
P/E ratio
24,40
52-wk high
€88,99
52-wk low
€69,77
EPS
€3,48
Shares outstanding
1,25 mjd.
No. of employees
75 k
News stories
From web sources and news partners
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOBelén Garijo | Paul Hudson
Employees74,8 k
Founded1973
HeadquartersParys, ÃŽle-de-France, Frankryk
SectorHealth Care
IndustryPharmaceutical industry
Websitesanofi.com
Last report
30 Okt. 2026
Fiscal period
Q3 2026
- / -
Revenue / Est. (EUR)
15,23 mjd. / 13,33 mjd.
+14,25%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
12,20 mjd.
11,24 mjd.
12,30 mjd.
15,23 mjd.
Cost of goods sold
3,63 mjd.
3,06 mjd.
2,89 mjd.
3,63 mjd.
Cost of revenue
3,63 mjd.
3,06 mjd.
2,89 mjd.
3,63 mjd.
Research and development expenses
2,29 mjd.
1,75 mjd.
2,23 mjd.
1,85 mjd.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,82 mjd.
2,33 mjd.
2,49 mjd.
2,31 mjd.
Operating expense
6,84 mjd.
5,94 mjd.
6,82 mjd.
6,90 mjd.
Total operating expenses
10,46 mjd.
9,00 mjd.
9,71 mjd.
10,53 mjd.
Operating income
1,74 mjd.
2,25 mjd.
2,59 mjd.
4,70 mjd.
Other non operating income
122,00 m.
-40,00 m.
-91,00 m.
-
EBT including unusual items
-1,16 mjd.
2,01 mjd.
828,00 m.
4,22 mjd.
EBT excluding unusual items
1,70 mjd.
2,14 mjd.
2,40 mjd.
4,58 mjd.
Income tax expense
-348,00 m.
420,00 m.
451,00 m.
1,20 mjd.
Effective tax rate
30,13%
20,85%
54,47%
28,29%
Other operating expenses
1,19 mjd.
1,33 mjd.
1,55 mjd.
2,18 mjd.
Net income
-801,00 m.
1,61 mjd.
343,00 m.
3,02 mjd.
Net profit margin
-6,56%
14,35%
2,79%
19,83%
Earnings per share
1,53
1,88
-
-
Interest and investment income
79,00 m.
60,00 m.
64,00 m.
77,00 m.
Interest expense
-
-138,00 m.
-153,00 m.
-222,00 m.
Net interest expenses
79,00 m.
-78,00 m.
-89,00 m.
-145,00 m.
Depreciation and amortization charges
-
-
-
-
EBITDA
3,49 mjd.
2,78 mjd.
3,83 mjd.
5,68 mjd.
Gain or loss from assets sale
-79,00 m.
-
-9,00 m.
9,00 m.
Upcoming events
AI content may include mistakes. Learn more
Google-programme